News
TCMD
16.25
+2.46%
0.39
Weekly Report: what happened at TCMD last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at TCMD last week (0311-0315)?
Weekly Report · 03/18 10:42
Are Investors Undervaluing Tactile Systems Technology (TCMD) Right Now?
NASDAQ · 03/14 13:40
Weekly Report: what happened at TCMD last week (0304-0308)?
Weekly Report · 03/11 10:39
Weekly Report: what happened at TCMD last week (0226-0301)?
Weekly Report · 03/04 10:42
Tactile Systems: Statement of changes in beneficial ownership of securities
Press release · 02/28 02:15
Zacks.com featured highlights include Griffon, Centrus Energy, Tactile Systems Technology and Copa Holdings
NASDAQ · 02/27 13:32
4 Stocks With Solid Net Profit Margin to Boost Portfolio Returns
NASDAQ · 02/26 12:48
Weekly Report: what happened at TCMD last week (0219-0223)?
Weekly Report · 02/26 10:51
Analysts Are Bullish on These Healthcare Stocks: Bicycle Therapeutics (BCYC), Tactile Systems Technology (TCMD)
TipRanks · 02/21 11:50
U.S. RESEARCH ROUNDUP-Home Depot, Palo Alto Networks, Wendys
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Home Depot, Palo Alto Networks, Wendys and Wendys among companies with revised targets. Discover Financial Services, Cardinal Health and other companies see analyst downgrades. Some analysts raised their target prices for the companies.
Reuters · 02/21 06:59
Why Tactile Systems Technology Stock Dropped Today
NASDAQ · 02/20 23:34
Tactile Systems: Annual report
Press release · 02/20 16:10
Tactile Systems Shares Drop 9% After 4Q Revenue Miss
Tactile Systems Technology shares were down 9% to $13.39 after the company's fourth-quarter revenue missed analysts' expectations. The medical-technology company reported quarterly revenue of $77.7 million, compared with $73.9 million in the same quarter last year.
Dow Jones · 02/20 15:56
Tactile Systems Technology Inc reports results for the quarter ended in December - Earnings Summary
Tactile Systems Technology Inc reports quarterly adjusted earnings of 35 cents per share for the quarter ended in December. Revenue rose 5.1% to $77.65 million from a year ago. The company reported quarterly income of $8.2 million. The average analyst rating on the shares is "strong buy"
Reuters · 02/20 14:31
Tactile Systems Technology (TCMD) Beats Q4 Earnings Estimates
NASDAQ · 02/20 13:40
Tactile Systems Tech Q4 2023 Adj EPS $0.37 Beats $0.22 Estimate, Sales $77.65M Miss $78.36M Estimate
Tactile Systems Tech reported quarterly earnings of $0.37 per share. The company reported quarterly sales of $77.65 million which missed the analyst consensus estimate of $78.36 million. This is a 5.08 percent increase over the same period last year.
Benzinga · 02/20 12:59
Tactile Systems Technology GAAP EPS of $0.35 beats by $0.16, revenue of $77.7M misses by $0.65M
Tactile Systems Technology, Inc. Reports Q4 GAAP EPS of $0.35, revenue of $77.7M misses by $0.-$0.65M. The company expects full year 2024 revenue to be in the range of $300.0 million to $305 million.
Seeking Alpha · 02/20 12:34
*Tactile Systems Tech Sees 2024 Rev $300M-$305M >TCMD
Dow Jones · 02/20 12:33
BRIEF-Tactile Systems Technology Q4 Revenue USD 77.7 Million Vs. IBES Estimate USD 78.4 Million
Tactile Systems Technology reports Q4 revenue of $77.7 million. Company expects FY revenue to grow 9-11% to $300 million. Q4 operating income was $11.8 million; Q4 adjusted EBITDA was $15.4 million.
Reuters · 02/20 12:30
More
Webull provides a variety of real-time TCMD stock news. You can receive the latest news about Tactile Systems through multiple platforms. This information may help you make smarter investment decisions.
About TCMD
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company providing therapies for people with chronic disorders. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. The Company markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. The Company's Entre system is a basic pneumatic compression device. Kylee, its free mobile application, helps patients learn about lymphedema.